Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Completed Phase 3 Interventional Results available

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

NCT00833248
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Goserelin, Bicalutamide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00004211
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA RNA-pulsed dendritic cell vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Early Phase 1 Interventional

Re-treatment 225Ac-J591 for mCRPC

NCT04576871
View directory record Official record
Conditions
Prostate Cancer
Interventions
225Ac-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

NCT01667536
View directory record Official record
Conditions
Prostate Cancer
Interventions
Drug: 99mTc-MIP-1404
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Duarte, California • Rochester, Minnesota • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Not applicable Interventional

Developing Inclusive Support and Intervention for Spanish-speaking Latiné Prostate Cancer Survivors

NCT06435871
View directory record Official record
Conditions
Prostate Cancer
Interventions
Expanded Prostate Cancer Index Composite and Decision Regret Scale
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Not applicable Interventional

MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer

NCT02303054
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bipolar Radiofrequency Focal Ablation
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 31, 2026, 6:38 AM EDT
Completed No phase listed Observational

The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer

NCT01545154
View directory record Official record
Conditions
Prostate Cancer
Interventions
Transperineal Ultrasound
Device
Lead sponsor
H. James Wallace, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 31, 2026, 6:38 AM EDT
Recruiting Early Phase 1 Interventional

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

NCT06888102
View directory record Official record
Conditions
High-risk Prostate Cancer
Interventions
Neoadjuvant Epigenetic Therapy
Drug
Lead sponsor
Edwin Posadas, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Active, not recruiting Phase 2 Interventional

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

NCT01410942
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT)
Other · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

NCT01414283
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA ADC
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 31, 2026, 6:38 AM EDT
Recruiting Phase 2 Interventional

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

NCT05832086
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fasting Mimicking Diet (FMD), Standard Anti-Cancer Diet
Behavioral
Lead sponsor
Stephen Freedland
Other
Eligibility
Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Not listed No phase listed Observational

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

NCT04100811
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
miR Scientific LLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
2,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Stockbridge, Georgia • Farmingdale, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 31, 2026, 6:38 AM EDT
Terminated Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

NCT01928485
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
active surveillance, Sunphenon, laboratory biomarker analysis, Questionnaire Administration
Other · Drug
Lead sponsor
Sanjay Gupta PhD
Other
Eligibility
45 Years to 85 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 31, 2026, 6:38 AM EDT
Active, not recruiting No phase listed Observational

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401
View directory record Official record
Conditions
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
147
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Terminated Phase 2 Interventional

Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer

NCT02459912
View directory record Official record
Conditions
Prostate Cancer
Interventions
Unilateral Nerve-Sparing Cryoablation of the Prostate, Precise Cryoablation System with IceRod Needles
Procedure · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 31, 2026, 6:38 AM EDT
Completed No phase listed Observational

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

NCT02228265
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 31, 2026, 6:38 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

NCT05766371
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Interventions
Pembrolizumab, 177Lu-PSMA-617
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Phase 3 Interventional Results available

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

NCT00365105
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Pain, Prostate Cancer
Interventions
Calcium, Vitamin D, zoledronic acid, Sm-153, Sr-89
Dietary Supplement · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
147
States / cities
Mobile, Alabama • Burbank, California • Carmichael, California + 116 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 31, 2026, 6:38 AM EDT
Recruiting No phase listed Observational

Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

NCT07184957
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

NCT01186601
View directory record Official record
Conditions
Neoplasms
Interventions
PET tracer (BAY94-9392)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 31, 2026, 6:38 AM EDT
Terminated Phase 1 Interventional

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

NCT00848601
View directory record Official record
Conditions
Prostate Cancer, Non-Hodgkins Lymphoma
Interventions
SGI-1776
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 31, 2026, 6:38 AM EDT
Active, not recruiting Not applicable Interventional Results available

MRI Guided SBRT for Localized Prostate Cancer

NCT03778112
View directory record Official record
Conditions
Prostate Cancer
Interventions
SBRT to whole prostate, IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions
Radiation
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 31, 2026, 6:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

NCT02200614
View directory record Official record
Conditions
Prostate Cancer Non-Metastatic, Castration-Resistant
Interventions
Darolutamide (Nubeqa, BAY1841788), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
55
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 31, 2026, 6:38 AM EDT
Terminated Not applicable Interventional Results available

Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer

NCT02307552
View directory record Official record
Conditions
Prostate Cancer
Interventions
UreScan
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 31, 2026, 6:38 AM EDT